From Wikipedia, the free encyclopedia
Motexafin lutetium
Names
Other names
Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
UNII
CC([O-])=O.CCC1=C2[N-]C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=[N]([Lu+3])C5=C/2)C(C)=C\3CCCO)=C1CC
Properties
C 52 H 72 Lu N 5 O 14
Molar mass
1166 .136 g·mol−1
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
Motexafin lutetium is a
texaphyrin , marketed as Antrin by Pharmacyclics Inc.
It is a photosensitiser for use in
photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in
photoangioplasty (photodynamic treatment of diseased arteries).
[1]
It is photoactivated by 732 nm light which allows greater depth of penetration.
[2]
Clinical trials
Phase II clinical trials were in progress in 1999.
[3]
A phase I trial for
prostate cancer reported in 2009.
[4]
References
^
Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease
Archived 2011-07-16 at the
Wayback Machine , 2002
^
http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
^
Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT
Archived 2012-07-13 at
archive.today , 1999
^ Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008).
"Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA" . Clinical Cancer Research . 14 (15): 4869–76.
doi :
10.1158/1078-0432.CCR-08-0317 .
PMC
2680073 .
PMID
18676760 .